Better Buy After Earnings: Moderna or Novavax?
Moderna (NASDAQ: MRNA) has outpaced Novavax (NASDAQ: NVAX) in just about every area this year. The company launched its coronavirus vaccine worldwide -- and has generated billions of dollars in revenue and profit. Moderna shares have climbed more than 126% year to date. The Novavax story has been quite different. The company fell behind on regulatory submissions. And investors still are waiting for a potential vaccine launch. So, it's no surprise the stock has gained much less than that of Moderna. It's climbed about 42% this year.
And then came both companies' third-quarter earnings reports. Moderna disappointed investors when profit and revenue missed analysts' forecasts -- and as it lowered guidance for 2021 vaccine revenue. Novavax's news was brighter. The company submitted regulatory requests for its vaccine candidate to several countries and seems back on track toward commercialization. Does this mean it's time to buy Novavax and avoid Moderna? Not so fast. Let's take a closer look at both to see which may be a better buy after the recent earnings reports.
Image source: Getty Images.
Source Fool.com
